Fernando Gomollon

Summary

Publications

  1. ncbi request reprint Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide
    Fernando Gomollon
    IBD Unit, Digestive Diseases Service, Hospital Clinico Universitario Lozano Blesa, Instituto de Investigación Sanitaria de Aragón IIS, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Zaragoza, Spain
    Drugs 73:1761-70. 2013
  2. doi request reprint Intravenous iron in inflammatory bowel diseases
    Fernando Gomollon
    IBD Unit, Digestive Diseases Service, Instituto de Investigación Sanitaria de Aragón, Hospital Clinico Universitario Lozano Blesa, CIBERehd, Zaragoza, Spain
    Curr Opin Gastroenterol 29:201-7. 2013
  3. doi request reprint Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU
    Fernando Gomollon
    Department of Gastroenterology, Hospital Clinico Universitario Lozano Blesa, Instituto de Investigacion Sanitaria, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Zaragoza, Spain
    Gastroenterol Hepatol 36:104-14. 2013
  4. doi request reprint [The future of inflammatory bowel disease from the perspective of Digestive Disease Week 2012]
    Fernando Gomollon
    Servicio de Aparato Digestivo, Hospital Clinico Universitario Lozano Blesa, Instituto de Investigación Sanitaria de Aragón IIS, Facultad de Medicina de Zaragoza y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Zaragoza, Spain
    Gastroenterol Hepatol 35:43-50. 2012
  5. doi request reprint [Constant evolution of key concepts in inflammatory bowel disease. Some perspectives from Digestive Disease Week 2011]
    Fernando Gomollon
    Hospital Clinico Universitario Lozano Blesa, ISS Aragón, Zaragoza, Espana
    Gastroenterol Hepatol 34:43-51. 2011
  6. ncbi request reprint [Treatment with anti-TNFalpha agents in Crohn's disease: what drug we have to use and when?]
    Fernando Gomollon
    Servicio de Aparato Digestivo, Hospital Universitario Lozano Blesa, Facultad de Medicina, Zaragoza, Espana
    Acta Gastroenterol Latinoam 38:133-45. 2008
  7. ncbi request reprint [Inflammatory bowel disease]
    Fernando Gomollon
    Hospital Clinico Universitario Lozano Blesa, Facultad de Medicina, IACS, CIBERehd, Zaragoza, Espana
    Gastroenterol Hepatol 31:42-6. 2008
  8. doi request reprint [Must immunomodulators be added to biological treatment in inflammatory bowel disease?]
    Fernando Gomollon
    Servicio de Aparato Digestivo, Hospital Clinico Universitario, IACS, CIBERehd, Zaragoza, Espana
    Gastroenterol Hepatol 33:43-53. 2010
  9. pmc Anemia and inflammatory bowel diseases
    Fernando Gomollon
    Gastroenterology Unit, Clinical Universitary Hospital Lozano Blesa, CIBERehd, Avenida San Juan Bosco 15, Zaragoza 50009, Spain
    World J Gastroenterol 15:4659-65. 2009
  10. ncbi request reprint Optimising acid inhibition treatment
    Fernando Gomollon
    Facultad de Medicina, Gastroenterology Service, Clinical University Hospital, Zaragoza, Spain
    Drugs 65:25-33. 2005

Detail Information

Publications29

  1. ncbi request reprint Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide
    Fernando Gomollon
    IBD Unit, Digestive Diseases Service, Hospital Clinico Universitario Lozano Blesa, Instituto de Investigación Sanitaria de Aragón IIS, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Zaragoza, Spain
    Drugs 73:1761-70. 2013
    ..With the correct use of available resources, anemia and iron deficiency should be well controlled in practically all IBD patients. ..
  2. doi request reprint Intravenous iron in inflammatory bowel diseases
    Fernando Gomollon
    IBD Unit, Digestive Diseases Service, Instituto de Investigación Sanitaria de Aragón, Hospital Clinico Universitario Lozano Blesa, CIBERehd, Zaragoza, Spain
    Curr Opin Gastroenterol 29:201-7. 2013
    ..Anemia and iron deficiency are the most common extraintestinal complications of inflammatory bowel diseases (IBDs) and are often undertreated. We review the evidence on intravenous (i.v.) iron overcoming the limitations of oral iron in IBD...
  3. doi request reprint Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU
    Fernando Gomollon
    Department of Gastroenterology, Hospital Clinico Universitario Lozano Blesa, Instituto de Investigacion Sanitaria, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Zaragoza, Spain
    Gastroenterol Hepatol 36:104-14. 2013
    ..Evidence-based clinical guidelines on Ulcerative colitis (UC) have been developed through a consensus, while GRADE methodology is the current standard for guideline development. This is the first one based on GRADE methodology on UC...
  4. doi request reprint [The future of inflammatory bowel disease from the perspective of Digestive Disease Week 2012]
    Fernando Gomollon
    Servicio de Aparato Digestivo, Hospital Clinico Universitario Lozano Blesa, Instituto de Investigación Sanitaria de Aragón IIS, Facultad de Medicina de Zaragoza y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Zaragoza, Spain
    Gastroenterol Hepatol 35:43-50. 2012
    ..New healthcare models will be developed that will progressively include greater participation among patients and nurses. The ability to predict new diagnostic and prognostic models will allow decisions to be more individualized...
  5. doi request reprint [Constant evolution of key concepts in inflammatory bowel disease. Some perspectives from Digestive Disease Week 2011]
    Fernando Gomollon
    Hospital Clinico Universitario Lozano Blesa, ISS Aragón, Zaragoza, Espana
    Gastroenterol Hepatol 34:43-51. 2011
    ....
  6. ncbi request reprint [Treatment with anti-TNFalpha agents in Crohn's disease: what drug we have to use and when?]
    Fernando Gomollon
    Servicio de Aparato Digestivo, Hospital Universitario Lozano Blesa, Facultad de Medicina, Zaragoza, Espana
    Acta Gastroenterol Latinoam 38:133-45. 2008
    ..In anycase, we think that the use of "biologics" will provoke a dramatic change in CD treatment in the next 10 years...
  7. ncbi request reprint [Inflammatory bowel disease]
    Fernando Gomollon
    Hospital Clinico Universitario Lozano Blesa, Facultad de Medicina, IACS, CIBERehd, Zaragoza, Espana
    Gastroenterol Hepatol 31:42-6. 2008
    ..However, its incident does fully justify surveillance, although more and more data show that the key point to diminish the incidence of cancer is a good control of inflammation...
  8. doi request reprint [Must immunomodulators be added to biological treatment in inflammatory bowel disease?]
    Fernando Gomollon
    Servicio de Aparato Digestivo, Hospital Clinico Universitario, IACS, CIBERehd, Zaragoza, Espana
    Gastroenterol Hepatol 33:43-53. 2010
    ..Although the evidence is thoroughly reviewed, the main perspective is that of the practicing clinician...
  9. pmc Anemia and inflammatory bowel diseases
    Fernando Gomollon
    Gastroenterology Unit, Clinical Universitary Hospital Lozano Blesa, CIBERehd, Avenida San Juan Bosco 15, Zaragoza 50009, Spain
    World J Gastroenterol 15:4659-65. 2009
    ..Thus, the clinician caring for IBD patients should have a comprehensive knowledge of anemia, and apply recently published guidelines in clinical practice...
  10. ncbi request reprint Optimising acid inhibition treatment
    Fernando Gomollon
    Facultad de Medicina, Gastroenterology Service, Clinical University Hospital, Zaragoza, Spain
    Drugs 65:25-33. 2005
    ..When seeking oral 'potent' acid inhibition (refractory gastro-oesophageal reflux disease, and perhaps Barrett's oesophagus), available data suggest that the pharmacological and clinical profiles of esomeprazole are slightly better...
  11. pmc Are we giving azathioprine too much time?
    Fernando Gomollon
    Hospital Clinico Universitario Lozano Blesa Zaragoza, Avenida San Juan Bosco 15, Zaragoza, Spain
    World J Gastroenterol 14:5519-22. 2008
    ..This recommendation concerns the use of azathioprine as a single maintenance drug, and is not necessarily applicable to patients receiving concomitant biological therapy...
  12. ncbi request reprint Thiopurine methyltransferase activity in Spain: a study of 14,545 patients
    Javier P Gisbert
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Universidad Autonoma, Playa de Mojácar 29, Urb, Bonanza, 28669, Boadilla del Monte, Madrid, Spain
    Dig Dis Sci 52:1262-9. 2007
    ....
  13. ncbi request reprint [Common errors in the management of outpatients with inflammatory bowel disease]
    Javier P Gisbert
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Universidad Autonoma, Madrid, Espana
    Gastroenterol Hepatol 30:469-86. 2007
  14. ncbi request reprint Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review
    Javier P Gisbert
    Department of Gastroenterology, University Hospital of La Princesa, Madrid, Spain
    Dig Dis Sci 47:471-88. 2002
  15. ncbi request reprint [Common errors in the management of the seriously ill patient with inflammatory bowel disease]
    Javier P Gisbert
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Universidad Autonoma, Madrid, Spain
    Gastroenterol Hepatol 30:294-314. 2007
  16. doi request reprint Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review
    Javier P Gisbert
    Gastroenterology Unit, Hospital Universitario de la Princesa, Madrid, Spain
    Am J Gastroenterol 103:1783-800. 2008
    ..Our aim was to conduct a review of AZA/MP-induced myelotoxicity in inflammatory bowel disease (IBD) patients...
  17. doi request reprint Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients
    Maria Chaparro
    Gastroenterology Unit, La Princesa and Instituto de Investigación Sanitaria Princesa IP, Madrid, Spain
    Inflamm Bowel Dis 19:1404-10. 2013
    ..To evaluate the safety of thiopurines in patients with inflammatory bowel disease. To identify predictive factors associated with the development of thiopurine-induced adverse events...
  18. ncbi request reprint [Infliximab therapy in ulcerative colitis: initial experience in two referral centers]
    Marcos Díez
    Servicio de Aparato Digestivo, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Espana
    Gastroenterol Hepatol 30:449-53. 2007
    ..To perform a descriptive analysis of our experience with infliximab in the treatment of ulcerative colitis (UC)...
  19. pmc Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases
    JosE Antonio Garcia-Erce
    Transfusion Medicine and Apheresis Unit, Haematology and Haemotherapy Regional Service, Miguel Servet University Hospital, Zaragoza 50009, Spain
    World J Gastroenterol 15:4686-94. 2009
    ..Finally, it must be stressed that a combination of methods used within well-constructed protocols will offer better prospects for blood conservation in selected IBD patients undergoing elective surgery...
  20. doi request reprint Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease
    Javier P Gisbert
    Gastroenterology Unit, Hospital Universitario de la Princesa, Madrid, and Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas CIBERehd, Spain
    Am J Gastroenterol 103:1299-307. 2008
    ..Anemia diagnosis and treatment must not be neglected in IBD patients, and several misconceptions should be promptly abandoned...
  21. ncbi request reprint Crohn's disease: a review of current treatment with a focus on biologics
    Julian Panes
    Department of Gastroenterology, Hospital Clinic, Barcelona, Spain
    Drugs 67:2511-37. 2007
    ..Further prospective studies will provide interesting insight into different mechanisms by which factors involved in the pathophysiology of Crohn's disease can be modulated...
  22. doi request reprint Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease
    Javier P Gisbert
    Gastroenterology Unit, Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain
    Inflamm Bowel Dis 15:1746-54. 2009
    ..Finally, in patients with Crohn's disease who have undergone ileocolonic resection, those with higher lactoferrin fecal levels might be more prone to postsurgical recurrence...
  23. ncbi request reprint [Thiopurine methyltransferase activity in inflammatory bowel disease. A study on 7046 Spanish patients]
    Javier P Gisbert
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Universidad Autonoma, Madrid, Spain
    Med Clin (Barc) 125:281-5. 2005
    ....
  24. doi request reprint [Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infrequent but important complication of infliximab in Crohn's disease]
    Alberto Mir Subías
    Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Zaragoza, Espana
    Gastroenterol Hepatol 36:81-5. 2013
    ..Azathioprine, interferon, and even natalizumab, may be used as alternatives in patients who require therapy...
  25. ncbi request reprint [Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference]
    Javier P Gisbert
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Madrid, Spain
    Med Clin (Barc) 125:301-16. 2005
  26. pmc Intravenous iron in digestive diseases: a clinical (re)view
    Fernando Gomollon
    Javier P Gisbert, MD, PhD Digestive Diseases Service, Hospital La Princesa, Madrid, CIBERehd, Spain
    Ther Adv Chronic Dis 1:67-75. 2010
    ..New formulations make treatment even easier and more convenient. Recent guidelines are available for inflammatory bowel diseases, and new guidelines in acute and chronic gastrointestinal bleeding are needed...
  27. ncbi request reprint Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants
    Angel Lanas
    Servicio de Aparato Digestivo, Hospital Clinico Zaragoza, CIBER HEPAD, Zaragoza, Spain
    Am J Gastroenterol 102:507-15. 2007
    ..Here, we report the effect of antisecretory drugs and nitrates on the risk of upper GI peptic ulcer bleeding (UGIB) associated with nonselective NSAIDs, aspirin, antiplatelet agents, and anticoagulants...
  28. doi request reprint Clinical patterns and outcomes of ischaemic colitis: results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study)
    Miguel A Montoro
    Department of Gastroenterology, Hospital San Jorge, Huesca, Spain
    Scand J Gastroenterol 46:236-46. 2011
    ..We performed such a study to evaluate the clinical presentation, outcome, and mortality as well as clinical variables associated with poor prognosis...
  29. pmc Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease
    Javier P Gisbert
    Javier P Gisbert, María Chaparro, Gastroenterology Unit, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 28006 Madrid, Spain
    World J Gastroenterol 17:3467-78. 2011
    ..Finally, thiopurine methyltransferase (TPMT) screening cannot substitute for regular monitoring because the majority of cases of myelotoxicity are not TPMT-related...